Parkman Healthcare Partners LLC holds a diversified book of 89 stocks worth $964.6M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Eli Lilly & Co and trimmed Boston Scientific Corp. Their largest long position is Stryker Corp at 5% of the equity book. They also disclosed $5.1M in put options (a bearish bet), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1777015/holdings"
Use Arkolith to show Parkman Healthcare Partners LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
98% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Stryker Corporation COM | $50.9M | 154.8K | 5.3% | ▲+47% Added · +49K sh | |
| 2 | Dexcom Inc COM | $43.3M | 689.8K | 4.5% | ▲+17% Added · +102K sh | |
| 3 | Kalvista Pharmaceuticals Inc COM | $36.9M | 1.84M | 3.8% | ▲+3.8% Added · +67K sh | |
| 4 | Insulet Corp COM | $32.9M | 156.6K | 3.4% | ▲+11% Added · +16K sh | |
| 5 | Eli Lilly & Co COM | $31.8M | 34.6K | 3.3% | ▲New New position | |
| 6 | PTC Therapeutics Inc COM | $29.4M | 431.4K | 3.0% | ▲+169% Added · +271K sh | |
| 7 | Xenon Pharmaceuticals Inc COM | $28.9M | 497.0K | 3.0% | ▲+222% Added · +343K sh | |
| 8 | Boston Scientific Corp COM | $28.2M | 448.8K | 2.9% | ▼−10% Reduced · −52K sh | |
| 9 | CVS Health Corp COM | $27.8M | 387.3K | 2.9% | ▼−14% Reduced · −63K sh | |
| 10 | Arcus Biosciences Inc COM | $26.1M | 1.21M | 2.7% | ▲+25% Added · +239K sh | |
| 11 | Livanova PLC SHS | $25.7M | 404.0K | 2.7% | ▼−1.7% Reduced · −7K sh | |
| 12 | Zimmer Biomet Holdings Inc COM | $24.4M | 269.6K | 2.5% | ▲+78% Added · +119K sh | |
| 13 | MBX Biosciences Inc COM | $23.9M | 800.0K | 2.5% | ▼−9.7% Reduced · −86K sh | |
| 14 | Ani Pharmaceuticals Inc COM | $21.6M | 280.6K | 2.2% | ▲+94% Added · +136K sh | |
| 15 | Syndax Pharmaceuticals Inc COM | $21.1M | 901.5K | 2.2% | ▲+57% Added · +327K sh | |
| 16 | Qiagen NV ORD SHARES | $20.0M | 500.0K | 2.1% | ▲New New position | |
| 17 | Envista Holdings Corporation COM | $18.1M | 711.7K | 1.9% | ▲New New position | |
| 18 | Eyepoint Inc COM NEW | $17.5M | 1.35M | 1.8% | ▲+25% Added · +267K sh | |
| 19 | Abbvie Inc COM | $16.3M | 75.0K | 1.7% | ▲New New position | |
| 20 | Biocryst Pharmaceuticals Inc COM | $16.3M | 1.71M | 1.7% | ▲+90% Added · +808K sh | |
| 21 | Iqvia Hldgs Inc COM | $14.8M | 86.7K | 1.5% | ▲+146% Added · +51K sh | |
| 22 | Agios Pharmaceuticals Inc COM | $13.7M | 403.5K | 1.4% | ▲+305% Added · +304K sh | |
| 23 | Illumina Inc COM | $13.6M | 110.4K | 1.4% | ▲New New position | |
| 24 | Edwards Lifesciences Corp COM | $13.4M | 167.2K | 1.4% | ▲+11% Added · +16K sh | |
| 25 | Neurocrine Biosciences Inc COM | $13.1M | 99.1K | 1.4% | ▼−14% Reduced · −16K sh | |
| 26 | Kiniksa Pharmaceuticals Intl ORD SHS CL A | $12.5M | 259.2K | 1.3% | ▼−61% Reduced · −406K sh | |
| 27 | Assembly Biosciences Inc COM NEW | $11.4M | 411.2K | 1.2% | ▲+65% Added · +162K sh | |
| 28 | Structure Therapeutics Inc SPONSORED ADS | $11.2M | 232.1K | 1.2% | ▲+322% Added · +177K sh | |
| 29 | McKesson Corp COM | $11.0M | 12.7K | 1.1% | ▼−65% Reduced · −24K sh | |
| 30 | Stoke Therapeutics Inc COM | $11.0M | 336.5K | 1.1% | ▼−22% Reduced · −94K sh | |
| 31 | Viridian Therapeutics Inc COM | $10.9M | 557.9K | 1.1% | ▼−29% Reduced · −230K sh | |
| 32 | Waystar Hldg Corp COM | $10.7M | 443.1K | 1.1% | ▲+20% Added · +74K sh | |
| 33 | Mineralys Therapeutics Inc COM | $10.3M | 380.1K | 1.1% | ▼−7.3% Reduced · −30K sh | |
| 34 | Edgewise Therapeutics Inc COM | $10.2M | 322.8K | 1.1% | ▼−25% Reduced · −105K sh | |
| 35 | Xeris Biopharma Holdings Inc COM | $10.0M | 1.72M | 1.0% | ▲+1.8% Added · +30K sh | |
| 36 | Tenet Healthcare Corp COM NEW | $9.5M | 50.1K | 1.0% | ▼−17% Reduced · −10K sh | |
| 37 | Artivion Inc COM | $9.2M | 252.0K | 1.0% | ▲+15% Added · +33K sh | |
| 38 | Nuvalent Inc COM | $9.0M | 88.1K | 0.9% | ▼−26% Reduced · −31K sh | |
| 39 | Alphatec Hldgs Inc COM NEW | $9.0M | 823.8K | 0.9% | ▲+197% Added · +547K sh | |
| 40 | Alnylam Pharmaceuticals Inc COM | $8.9M | 26.9K | 0.9% | ▼−44% Reduced · −21K sh | |
| 41 | Axogen Inc COM | $8.9M | 268.2K | 0.9% | ▲+7.1% Added · +18K sh | |
| 42 | Immunome Inc COM | $8.8M | 403.5K | 0.9% | ▲+45% Added · +126K sh | |
| 43 | Amylyx Pharmaceuticals Inc COM | $8.6M | 621.5K | 0.9% | ▲+63% Added · +240K sh | |
| 44 | Idexx Labs Inc COM | $8.4M | 15.0K | 0.9% | ▲New New position | |
| 45 | Waters Corp COM | $7.9M | 26.4K | 0.8% | ▼−37% Reduced · −15K sh | |
| 46 | Adaptive Biotechnologies Cor COM | $7.7M | 551.8K | 0.8% | ▲+37% Added · +150K sh | |
| 47 | Upstream Bio Inc COM | $7.1M | 786.8K | 0.7% | ▼−5.7% Reduced · −48K sh | |
| 48 | Erasca Inc COM | $6.6M | 406.7K | 0.7% | ▲New New position | |
| 49 | Apogee Therapeutics Inc COM | $6.5M | 77.7K | 0.7% | ▼−40% Reduced · −52K sh | |
| 50 | Cooper Cos Inc COM | $6.4M | 89.9K | 0.7% | ▼−28% Reduced · −35K sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | MODERNA INC | $5.1M | 100K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.